Invention Grant
- Patent Title: Predicting response to a HER inhibitor
- Patent Title (中): 预测对HER抑制剂的反应
-
Application No.: US12074229Application Date: 2008-03-01
-
Publication No.: US07981418B2Publication Date: 2011-07-19
- Inventor: Lukas C. Amler , Merrill Birkner , Chin-Yu Lin , Joachim Moecks , Andreas Strauss
- Applicant: Lukas C. Amler , Merrill Birkner , Chin-Yu Lin , Joachim Moecks , Andreas Strauss
- Applicant Address: US CA South San Francisco US NJ Nutley
- Assignee: Genentech, Inc.,Hoffmann-La Roche Inc.
- Current Assignee: Genentech, Inc.,Hoffmann-La Roche Inc.
- Current Assignee Address: US CA South San Francisco US NJ Nutley
- Agent Wendy M. Lee
- Main IPC: A61K39/395
- IPC: A61K39/395
Abstract:
The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab.It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab.In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
Public/Granted literature
- US20100008975A1 Predicting response to a HER inhibitor Public/Granted day:2010-01-14
Information query
